Quantcast

Latest Sipuleucel-T Stories

2011-06-29 19:04:00

SEATTLE, June 29, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE(®) (sipuleucel-T) across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. The Los...

2011-06-23 15:30:00

NEW YORK, June 23, 2011 /PRNewswire/ -- For years, researchers have dreamed of curing prostate cancer with targeted drugs that could modulate the body's own immune system to attack and destroy malignant cancer cells. Recent approvals of immuno-modulatory drugs Provenge and Yervoy represent considerable progress in this domain, as they have already been shown to improve survival rates in certain types of metastatic prostate cancer. Over 20 other such drugs are expected to seek approval in...

2011-06-16 05:00:00

SEATTLE, June 16, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the NASDAQ OMX 26th Investor Program in London on June 21, 2011 at 9:30 a.m. GMT (4:30 a.m. ET). The presentation will be webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations...

2011-06-13 17:32:00

SEATTLE, June 13, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., President and Chief Executive Officer received the Ernst & Young Entrepreneur Of The Year(®) 2011 Pacific Northwest Award in the Emerging Sciences category. Dr. Gold has served as CEO of Dendreon since 2003, and under his leadership the company last year received U.S. Food and Drug Administration approval for PROVENGE®...

2011-06-03 12:24:15

Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data being presented by researchers from the Kimmel Cancer Center at Jefferson at the 2011 American Society of Clinical Oncology annual meeting in Chicago on Saturday, June 4. (ABSTRACT #4534) In an exploratory, multi-institutional analysis, researchers administered the vaccine APC8015F to a group of patients...

2011-05-20 05:00:00

SEATTLE, May 20, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences: ThinkEquity Annual Healthcare Conference in New York City, NY on May 25, 2011 at 1:00 p.m. ET Goldman Sachs Annual Global Healthcare Conference in Rancho Palos Verdes, CA on June 7, 2011 at 2:00 p.m. PT The presentations will be webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen...

2011-05-19 07:15:00

AUBURNDALE, Mass., May 19, 2011 /PRNewswire/ -- Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak(TM), its lead agent for patients with newly diagnosed prostate cancer. The trial is expected to accrue 711 patients starting mid-2011 with definitive results expected by 2015. The randomized study will...

2011-05-18 17:00:00

SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 2011 American Society of Clinical Oncology annual meeting in Chicago, Illinois. "Time to Disease-Related Pain After Sipuleucel-T in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Results from 3 Randomized Phase 3 Trials," abstract #4661. McCormick Place Hall A (Poster...

2011-05-18 17:00:00

SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced three abstracts accepted for poster presentation detailing clinical trial plans for PROVENGE® (sipuleucel-T) and the clinical trial of DN24-02 in bladder cancer at the upcoming American Society for Clinical Oncology annual meeting in Chicago, Illinois. The three abstracts will be presented on Monday, June 6, 2011, from 8:00 a.m. to 12:00 p.m. CT in the McCormick Place Hall A at the...

2011-05-16 13:50:00

MAYWOOD, N.J., May 16, 2011 /PRNewswire/ -- New Jersey Center for Prostate Cancer & Urology is among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies. PROVENGE was approved by the U.S. Food and Drug Administration (FDA) for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related